Voltar à classificação

ICU Medical, Inc. (ICUI)

NEUTRAL
HealthcareMedical Instruments & SuppliesUnited States

Fundamental

49

Preço

$183.10

Capitalização de Mercado

$4.55B

Parte 1 · Quanto vale a empresa

Visão Geral

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

Balanço & Liquidez

Receita

$2.16B

Últimos 12 meses (até 30/06/2026)

Resultado Líquido

$30M

Últimos 12 meses (até 30/06/2026)

Fluxo de Caixa Livre

$92M

Capital Próprio Total

$2.12B

Passivo Total

$1.93B

Rácio de Liquidez

2.43

Cobertura de Juros

0.87

Dívida/EBITDA

5.28

Resultados Por Ação

Receita & Resultado Líquido

Fluxo de Caixa Livre

Decomposição dos Resultados

Demonstração histórica

Margens ao longo do tempo

A dívida ao longo do tempo

Quanto pesa a dívida

Grelha do crescimento

Crescimento — Receitas

Estimativa de Valor Justo

General caseSobrevalorizada

Valor Justo

$102.68

Preço Atual

$183.10

Margem de Segurança

-78.3%

Intervalo de Valor Justo

$66.74 - $138.62

Métodos de Estimativa

Analyst price target:$193.38
Discounted cash flow (DCF):$117.21
Earnings multiple (P/E):$22.75
Graham growth formula:$8.90
Earnings power value (EPV):$29.87
Justified P/B:Not enough data to compute it
Dividend discount (Gordon):Not enough data to compute it
P/FFO, funds from operations:Not enough data to compute it
Mid-cycle earnings:$234.96
Revenue multiple:Not enough data to compute it
Consenso dos Analistas:Compra Forte (12B / 1H / 0S)
Última Surpresa de Resultados:+21.43%

Métricas de Avaliação

Rácio P/E

153.40

ROE

0.0%

Rácio P/B

2.12

P/FCF

29.87

Margem Bruta

39.1%

ROIC

1.6%

Radar de Rentabilidade

Value Creation (Economic Moat)

ROIC

1.6%

WACC

8.5%

ROIC − WACC

-6.8 pp

ROIC is below the cost of capital — the company is destroying value for every dollar invested.

Critérios de Análise Fundamental

Aprovado (14)

  • Gross Margin 39.1%
  • P/FCF 29.87
  • P/B Ratio 2.12
  • Debt/Equity ratio
  • Positive Free Cash Flow
  • Current Ratio
  • Debt/EBITDA
  • Revenue Growth 5Y 11.9%
  • Analyst Consensus 92% Buy
  • Earnings Surprise avg 20.3%
  • Earnings Quality (OCF/NI) 7.86
  • Share Dilution 0.1%
  • Net Margin Trend 1.4% vs -1.6%
  • Piotroski F-Score 7/9

Reprovado (12)

  • EPS shows upward trend
  • EPS CAGR -19.56%
  • Price CAGR 2.18%
  • ROIC 1.6%
  • Operating Margin 3.3%
  • CapEx intensity
  • Interest Coverage
  • Return on Tangible Assets
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • ROE 2.2%

Indisponível (2)

  • Dividend Payout NaN%
  • PEG Ratio (need PE > 0 and growth > 0)

Piotroski F-Score

7/9

Saúde financeira sólida

score
criteria

Qualidade dos Resultados

7.86

Alta qualidade: resultados respaldados por caixa

Diluição de Ações

0.1%

Número de ações estável

Governação

Equipa Executiva

NomeCargoIdade
Mr. Vivek JainCEO & Chairman of the Board53
Mr. Daniel WoolsonPresident48
Mr. Brian Michael BonnellCFO & Treasurer51
Mr. Christian B. VoigtlanderChief Operating Officer57
Ms. Virginia Ruth SanzoneCorporate VP, General Counsel, Secretary & Compliance Officer50
Ben SousaChief Information Officer-
Olivia BarrallVice President of Human Resources-

Risco de Auditoria

5

Risco do Conselho

4

Risco de Remuneração

4

Risco dos Direitos dos Acionistas

5

Parte 2 · O preço e o momento de entrar

Esta parte não serve para saber se a empresa vale: serve para escolher quando comprá-la, depois que os fundamentos te convenceram. Dentro: análise técnica, potencial, quedas históricas, exposição gama.

Latest News

Recent headlines for ICUI, sourced from Markets Gazette.

No recent news for ICUI.